Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

MoonLake Immunotherapeutics AG

Contributing Author

Recent Articles by MoonLake Immunotherapeutics AG

Aug-10	MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results MLTX -5.09% GlobeNewswire
Jun-23	MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering MLTX -5.75% GlobeNewswire
Jun-22	MoonLake Immunotherapeutics Announces Proposed Public Offering MLTX +15.36% GlobeNewswire
Jun-21	MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 MLTX GlobeNewswire
May-10	MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results MLTX GlobeNewswire
Mar-28	MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting MLTX GlobeNewswire
Feb-22	MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results MLTX GlobeNewswire
Feb-02	MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day MLTX GlobeNewswire
Jan-08	MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day MLTX +27.02% GlobeNewswire
Nov-05	MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering MLTX GlobeNewswire
Nov-05	MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab MLTX GlobeNewswire
Sep-28	MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab MLTX GlobeNewswire
Aug-05	MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update MLTX GlobeNewswire
May-12	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update MLTX GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)